Filing Summary
Company: ChronoScale Holdings Corporation (Nasdaq: CHRN). Filing: Form 8-K, reporting an event dated October 2, 2026; signed October 6, 2026.
Business Context
The filing concerns executive and board changes following the September 30, 2026 sale of the company’s wholly owned subsidiary, Ekso Bionics, Inc. It does not provide operating or financial results for a reporting period.
Executive Changes and Compensation
- Scott Davis, Ekso’s CEO and a member of ChronoScale’s board, resigned from the board effective October 3, 2026. The company reported no disagreements leading to his resignation.
- On October 2, the company granted Davis 51,626 restricted stock units, which fully vested on the grant date. The filing does not state their value.
- A release agreement provides for a $709,500 lump-sum cash payment, less applicable withholdings and deductions, payable within 30 days of execution. Payment is subject to Davis’s compliance with the agreement and continuing restrictive covenants.
- The payment is in lieu of and fully satisfies any payment or benefit otherwise due under Davis’s November 5, 2025 Change in Control and Severance Agreement. The release agreement does not change his separate Phantom Performance-Based Restricted Stock Unit Agreement.
Financial Metrics and Outlook
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or guidance figures. It does not quantify the value of the vested RSUs or describe the sale proceeds or their financial effects.
Important Facts to Verify
- Sale terms, proceeds, and the transaction’s effect on ChronoScale’s remaining business and financial position.
- The value and accounting treatment of the 51,626 vested RSUs and the $709,500 release payment.
- Whether the release payment conditions and continuing restrictive covenants are satisfied.
- Any continuing obligations or potential value under the Phantom Performance-Based Restricted Stock Unit Agreement.